Therapy Areas: Oncology
Physiomics secures new modelling contract with Numab Therapeutics
28 January 2026 - Mathematical modelling, data science and biostatistics company Physiomics plc (AIM: PYC) announced on Wednesday that it has been awarded a new contract by long-standing client Numab ...
HanchorBio partners with WuXi Biologics for development and manufacturing of next-gen bi- and multi-functional fusion programmes
27 January 2026 - HanchorBio Inc (TPEx:7827), a clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, announced on Monday that it has ent...
MS Pharma enters strategic partnership with Hetero Group
27 January 2026 - MS Pharma Group, a Jordan-based pharmaceutical company, announced on Monday that it has entered into a strategic partnership with Hetero Group, a manufacturer of Active Pharmaceutica...
PhotonPharma adds Dr. William Warren to board
23 January 2026 - PhotonPharma Inc, a developer of autologous cancer immunotherapies, announced on Thursday the appointment of William Warren, Ph.D. to its board of directors.PhotonPharma says that Dr...
Mabwell reports first patient dosed with 7MW4911 in US trial
23 January 2026 - Chinese biopharmaceutical company Mabwell (SHA:688062) announced on Thursday that the first patient has been dosed in a US clinical trial of its independently developed novel CDH17-t...
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
22 January 2026 - Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq: ATOS) announced on Wednesday that The Healthcare Technology Report has recognized the company's founder...